2 unknown. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow 202-CoV standard dose: new trials by email Literature Review of 202-CoV standard dose trials Research Report on 202-CoV standard dose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19 202-CoV low adjuvant dose, 202-CoV low antigen dose, 202-CoV standard dose - COVID-19 | Phase 2 | Unknown | Shanghai Zerun Biotechnology Co.,Ltd | 528 | 2021-07-31 | 2023-04-19 |
| Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19 202-CoV low adjuvant dose, 202-CoV low antigen dose, 202-CoV standard dose - COVID-19 | Phase 1 | Unknown | Shanghai Zerun Biotechnology Co.,Ltd | 72 | 2021-07-12 | 2023-04-19 |
COVID-19 (2)
Shanghai Zerun Biotechnology Co.,Ltd (2)
China (2)